F.D.A. Sees Promise in Alzheimer’s Imaging Drug
New York Times Article
By GINA KOLATA
Published: January 20, 2011
An advisory committee to the Food and Drug Administration recommended unanimously Thursday that the agency approve the first test — a brain scan — that can show the characteristic plaques of Alzheimer’s disease in the brain of a living person. The approval was contingent on radiologists agreeing on what the scans say and doctors being trained in how to read the scans.
Where are we with biomarker diagnosis and other tests for Alzheimer's Disease?
Watch Steven T. DeKosky, MD discuss testing issues in the following short video clips.
Copyright © 2011 by the Rector and Visitors of the University of Virginia
Office of Continuing Medical Education
P.O. Box 800711 Charlottesville, VA 22908
phone 434–924–5310 | fax 434–982–1415
Programming and Development by
